Home » Health » Corona hope and pray: medicine instead of injection. A new cure is being researched

Corona hope and pray: medicine instead of injection. A new cure is being researched

A drug against corona with advantages over a vaccination? Sounds too good to be true, but these researchers are currently working on it.

Details on the remedy are available from AstraZeneca.

  • The new corona vaccine * from BioNTech * has been administered throughout Germany since December 27, 2020.
  • Scientists in the UK have begun testing an innovative antibody-drug treatment that they hope could provide immediate protection against COVID-19.
  • The potential corona cure has a ton of advantages over vaccines.
  • AstraZeneca and University College London Hospitals (UCLH) are meanwhile working on a new drug against the coronavirus *.

Corona hope: drug instead of syringe? Researching new remedies

British researchers are currently testing a new drug against the coronavirus in a study. The study is already in the crucial third phase, but time is running out. Perhaps that is why the researchers gave the complicated test procedure the catchy name “Storm Chaser”? One thing is certain: the goals are very ambitious.

If the British plans can be implemented, the new drug would be tantamount to an anti-corona revolution. Because the potential cure for Corona has a lot to offer and would put all previous vaccinations in the shade.

Cure against Corona as an alternative to the vaccine

The drug, known as AZD7442, is being developed by AstraZeneca. It consists of two artificially generated antibodies that play different roles. The drug provides immediate cure for the coronavirus without the need for further treatment.

The antibody cocktail can also protect people who have already been infected with the coronavirus. A severe course of the disease is prevented and on top of that, the body develops the necessary immunity against other possible infections.

This method is already a good practice. Even if rabies is suspected, antibodies that eliminate the virus are administered.

The Storm Chase study researchers believe a long-acting antibody (LAAB) called AZD7442, developed by AstraZeneca, can provide immediate, long-term protection to people recently exposed to the coronavirus.

We know that this combination of antibodies can neutralize the virus. Therefore, we hope that giving this treatment by injection can lead to immediate protection from developing COVID-19 in people who have been exposed to the virus when it is too late for a vaccine, Houlihan said.

The second Provent study is looking at the use of AZD7442 in people who may not respond to vaccination, e.g. B. if someone has a weakened immune system or has an increased risk of COVID-19 infection due to factors such as age and existing illnesses.

We will be recruiting people who are older or in long-term care who have diseases such as cancer and HIV that can affect their immune systems’ ability to respond to a vaccine.

We want to reassure everyone for whom a vaccine does not work that we can offer an alternative that is just as protective, ”said Dr. Nicky Longley, UCLH infectious disease advisor and lead Provent study.

Dr. Catherine Houlihan, a virologist at University College London Hospitals NHS Trust (UCLH) who leads a study called Storm Chaser on drug AZD7442, said, “If we can prove this treatment works and prevents people exposed to the virus , continuing to contract COVID-19, it would be an exciting addition to the arsenal of weapons being developed to fight this terrible virus. “

Details about Corona

The World Health Organization (WHO) on Thursday listed Pfizer / BioNTech’s vaccine as the first such drug to receive emergency validation since the coronavirus outbreak began a year ago. A year ago, when a new coronavirus, SARS-CoV-2, that led to the COVID-19 pandemic was first identified in Beijing, there were no known cases outside of China. But today there are more than 83 million COVID-19 cases and more than 1.8 million confirmed deaths worldwide, according to the Johns Hopkins University of Medicine in the US.

On December 2, the UK became the first western country to give the green light to a vaccine against COVID-19 made by US pharmaceutical giant Pfizer and German biotechnology company BioNTech. Russia had already given its Sputnik V vaccine. Up to 50 countries, including the US and the EU, have now approved vaccines for emergency or normal use. The WHO emergency list gives countries the opportunity to speed up their regulatory approval processes for the import and administration of the vaccine.

It also enables the UN Children’s Fund UNICEF and the Pan American Health Organization to procure the vaccine for distribution to countries in need. On December 19, the United States approved the Moderna vaccine as the second drug for use against COVID-19.

On Wednesday, the UK Medicines Agency approved Oxford-AstraZeneca’s COVID-19 vaccine as the first country for use in the UK.

This is particularly good news for people who cannot be vaccinated for health reasons. In addition, the remedy promises immediate protection against the dangerous Covid 19 disease after just one vaccination.

Corona cure – advantages over vaccination

The advantages over a conventional vaccination are obvious:

In contrast to BioNTech’s mRNA-based vaccine, AstraZeneca’s corona regimen is a faster-acting vaccine. The vaccinations must be given at two separate times (spread over a period of weeks) to ensure sufficient safety.

For those who have already come into contact with the coronavirus and may have been infected with the pathogen, the vaccination will be too late! Not so with the drug from AstraZeneca: It should help up to eight days after a possible infection with the coronavirus. In addition, the manufacturer promises immunity to the virus for up to a year.

Cure for Corona: Alternative for people without a vaccination

If the results of the study meet the high expectations, the drug could be approved as an emergency drug as early as the spring, reports the British newspaper “Guardian”.

Another study by the University College London Hospitals NHS Foundation Trust (UCLH) is also testing whether the new drug against corona is also suitable for patients for whom a vaccination is not an option. This is especially true for people who suffer from an immune deficiency or who have cancer.

The same applies to allergy sufferers who could be at risk from side effects of the BioNTech * mRNA vaccine – even if possible side effects occur extremely rarely.


Leave a Comment